Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values

Paschalis, E. P., Gamsjaeger, S., Klaushofer, K., Shane, E., Cohen, A., Stepan, J., Pavo, I., Eriksen, E. F., Taylor, K. A., & Dempster, D. W. (2022). Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. Bone, 162, 116478. https://doi.org/10.1016/j.bone.2022.116478
Authors:
Eleftherios P Paschalis
Sonja Gamsjaeger
Klaus Klaushofer
Elizabeth Shane
Adi Cohen
Jan Stepan
Imre Pavo
Erik F Eriksen
Kathleen A Taylor
David W Dempster
Affiliated Authors:
Elizabeth Shane
Adi Cohen
David W Dempster
Author Keywords:
bone quality
bone formation
postmenopausal osteoporosis
teriparatide
human iliac crest biopsies
raman spectroscopy
Publication Type:
Article
Unique ID:
10.1016/j.bone.2022.116478
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: